Aberrant activation of the IL6R/JAK1/STAT3 signaling pathway is implicated in mediating de novo resistance to tyrosine kinase inhibitors (e.g., afatinib, erlotinib, dacomitinib) in H1975 and PC9-GR NSCLC cells harboring the T790M mutation [36]. This evidence concerns the gene IL6R and non-small cell lung carcinoma.